Abstract
Purpose. The purpose of the study was to determine how air flow profiles affect fine particle fractions (FPF) (<5 mu m) from dry powder aerosol formulations and whether laser diffraction (LD) could be used to measure FPF of aerosols generated by variable flows. Materials and Methods.Carrier-based formulations containing 1.5% w/w micronized salbutamol base blended with the 63-90 mu m fraction of alpha-lactose monohydrate or sorbitol or maltose were aerosolised from a model glass device using either a constant flow rate or a predetermined flow profile. The FPFs of the same aerosolised particles were first measured by LD and then by a liquid impinger. Volunteer inhalation airflow profiles and 3-phase (acceleration, constant flow rate and deceleration) square wave airflow profiles were generated using the Electronic Lung (TM) and an Inhalation Profile Recorder. Similar experiments were conducted for a carrier-free formulation from the Bricanyl Turbohaler (TM). Results. Salbutamol FPFs of all carrier-based formulations were found to increase by increasing the initial flow increase rate (FIR) from 200 to 600 l min(-1) s(-1) although they could be placed in an increasing order of maltose blend <sorbitol blend <lactose blend. A significant linear correlation was found between FPFs measured by LD and by inertial impaction (R-2=0.95, p <0.01, ANOVA). For the Bricanyl Turbohaler (TM), increasing FIR from 120 to 600 l min(-1) s(-1) for a constant peak flow rate (PFR) of 60 l min(-1) increased the mean Terbutaline FPF from 18.2% to 45.5%. For the volunteer inhalation profiles, a higher FIR tended to be associated with higher PFR, leading to a marked increase in drug FPF due to the combined effect of FIR and PFR. Conclusion. Drug FPF from either carrier-free or carrier-based formulations is determined by both FIR and PFR. LD is a viable technique to measure the performance of dry powder aerosol formulations at realistic inspiratory flow profiles
Original language | English |
---|---|
Pages (from-to) | 361 - 369 |
Number of pages | 9 |
Journal | Pharmaceutical Research |
Volume | 24 |
Issue number | 2 |
DOIs | |
Publication status | Published - Feb 2007 |